Phase III ADMIRE-CD trial

June 23, 2017June 24, 2017

Swiss Regulators to Consider Cx601 as a Treatment for Crohn’s-related Anal Fistulas

News

Swiss regulators have agreed to review Cx601 as a treatment for Crohn’s-disease-related skin sores known as complex perianal fistulas. The Swiss Agency for Therapeutic Products, or Swissmedic, granted orphan drug status to the stem ... Read more

August 25, 2015August 25, 2015

TiGenix Lead Compound Cx601 Efficient in Treating CD Patients’ Perianal Fistulas

Crohn's Disease, News

TiGenix, a leading biopharmaceutical company developing therapeutics based on adult stem cells, recently announced the results of the Phase III ADMIRE-CD clinical trial, testing the company’s lead compound Cx601 on Crohn’s disease ... Read more